Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCRM4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $16,584.13 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. The delivery order, issued on December 4, 2025, with an ultimate completion date of December 26, 2025, was made without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors for the Department of Defense.
DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical supply chain, leveraging its established performance on numerous delivery orders to fulfill specialized pharmaceutical requirements for military healthcare facilities worldwide. The company's comprehensive product portfolio includes branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals supporting diverse therapeutic categories. As part of the PPV-G GEN V initiative, which authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for recurring medical supply needs, DMS Pharmaceutical Group's $499.999 billion ceiling contract extends through December 31, 2036, positioning the company as a key pharmaceutical supplier for Department of Defense operations globally.
Quick answers
Who was awarded contract SPE2DR26FCRM4?
SPE2DR26FCRM4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 4, 2025.
How much is contract SPE2DR26FCRM4 worth?
The government has obligated $16,584 on SPE2DR26FCRM4.
Is contract SPE2DR26FCRM4 an order under another contract?
Yes. SPE2DR26FCRM4 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRM4 competed?
The extent of competition for SPE2DR26FCRM4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award